Related Experiment Video
Updated: May 1, 2026
12:59
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
33.7K
Current and Emerging Therapies Targeting the IL-23/IL-17 Axis in Psoriasis
Sang-Jun Han1, Go-Yeon Jung1, Gyeong-Cheon Lee1
1Division of Life Sciences, College of Life Science and Bioengineering, Incheon National University, Incheon 22012, Republic of Korea.
Biomolecules & Therapeutics
|April 30, 2026
Summary
The interleukin-23 (IL-23)/interleukin-17 (IL-17) pathway drives psoriatic inflammation, leading to effective biologic therapies. New non-injectable treatments and advanced technologies offer improved psoriasis management options.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- The interleukin-23 (IL-23)/interleukin-17 (IL-17) axis is central to psoriatic inflammation.
- IL-23 promotes type 17 immune cells, which release cytokines that activate keratinocytes and recruit inflammatory cells.
Purpose of the Study:
- To review the current understanding of the IL-23/IL-17 pathway in psoriasis pathogenesis.
- To provide an overview of current and emerging therapies targeting this pathway.
- To discuss challenges and future directions in precision immunotherapy for psoriasis.
Main Methods:
- Review of experimental and clinical evidence.
- Analysis of approved and emerging therapeutic strategies.
- Discussion of biological and translational challenges.
Main Results:
- IL-23/IL-17 pathway is a validated target for psoriasis treatment.
- Biologic therapies targeting IL-17 or IL-23 have significantly improved psoriasis management.
- Non-injectable therapies (oral/topical small molecules) are expanding treatment options.
- Advanced technologies are refining therapeutic discovery and targeting.
Conclusions:
- The IL-23/IL-17 pathway remains a critical focus for psoriasis immunotherapy.
- Development of non-injectable and precision therapies is advancing psoriasis care.
- Addressing biological and translational challenges is key for future treatment strategies.
Related Concept Videos
01:24T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:22iPS Cell Differentiation
2.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.2K
01:21EPS and iPS Cells in Disease Research
3.2K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.2K